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Background: Aristolochic acid nephropathy (AAN) is a progressive chronic
kidney disease related to the use of Chinese herbal medicine and is charac-
terized by extensive tubulointerstitial fibrosis and inflammation with macro-
phage infiltration. However, treatment of AAN remains ineffective. Thus,
the present study aimed to develop a new therapeutic strategy for chronic
AAN by targeting macrophages with a selective inhibitor of tyrosine kinase
activity of macrophage colony-stimulating factor receptor (fms-I).
Methods: Chronic AAN was induced in C57BL/6 mice by intraperitoneal in-
jection of aristolochic acid at a dose of 5 mg/kg every other day for 4 weeks.
fms-I in an optimal dose of 10 mg/kg twice daily (i.p) was given at the begin-
ning of induction of AAN or at the established AAN on day 14. The therapeu-
tic effect of fms-I on chronic AAN was examined at day 28.
Results: Treatment with fms-I largely suppressed F4/80+ macrophage and
CD3+ T cell infiltration and upregulation of proinflammatory cytokines (MIF,
TNFa, MCP-1), resulting in protection against acute and chronic AAN by
inhibiting 24-hour proteinuria, elevated levels of serum creatinine, upregu-
lation of KIM-1, and progressive renal fibrosis including accumulation of a-
SMA+ myofibroblasts and collagen I. Moreover, administration of fms-I to
the established AAN at day 14 also halted the disease progression of chronic
AAN at day 28. Further studies revealed that the therapeutic effect of fms-I
on chronic AAN was associated with blockade of both NF-kB and TGF-b/Smad
pathways.Conclusion: Macrophages play a pathogenic role in the development of
chronic AAN. Targeting macrophages with fms-I has therapeutic potential
for chronic AAN.http://dx.doi.org/10.1016/j.hkjn.2015.09.0070059
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Objective: Autosomal dominant polycystic kidney disease (ADPKD), an
inherited disease characterized by massive enlargement of fluid-filled cysts
in the kidney with an incidence rate of 1:1000e1:400, is a common cause of
renal failure. There is no effective therapy for ADPKD. Repulsive guidance
molecular b (RGMb), a co-receptor for bone morphogenetic protein
signaling and also a ligand for neogenin, is expressed at the epithelial cells
in kidney. RGMb has been reported to induce apoptosis in renal tubular
cells. The aim of this study was to determine if RGMb played a role in
ADPKD development.
Methods: MDCK cyst model, embryonic kidney cyst model and Pkd1flox/+;
Ksp-Cre PKD mouse model were used to assess the effect of RGMb in ADPKD.
Results: The experimental results showed that RGMb overexpression inhibited
MDCK cyst formation in 3D collagen matrix. Compared with control MDCK cells
whose cysts contained a single lumen with forskolin stimulation, RGMb-MDCK
cells sprawled into the colonies without cystic structure. A few of identifiable
cysts containedmultiple smaller lumensand thickerwalls. H&E staining showed
that RGMbnull kidneyshad interstitial hyperplasia anddecreased tubular struc-
tures, especially in theboundary area of renal cortex andmedulla. DBA staining
revealed less branched uretic bud in E13.5 RGMb null mouse embryonic kidney,
which suggested that deficiency of RGMbwould retard uretic budbranchingand
negatively modulate collecting duct development. Western blot analysis
exhibited increased phosphorylation of Smad1/5/8 in RGMb-MDCK cells, indi-
cating BMP-Smad1/5/8 pathway was important in ADPKD development.
Conclusion: Our data suggest that RGMb plays an important role in kidney
development and inhibits ADPKD by regulating BMP-Smad1/5/8 pathway.http://dx.doi.org/10.1016/j.hkjn.2015.09.0080061
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Objective: We demonstrated that the outcome of treating AL amyloidosis
with bortezomib-dexamethasone (BD) induction followed by autologous
hematopoietic stem cell transplantation (ASCT) was superior to the
outcome of the ASCT treatment alone previously. To further improve the
hematologic response rate, we conducted a prospective trial of bortezo-
mib before, in and after ASCT in patients with newly diagnosed AL
amyloidosis.
Methods: Newly diagnosed AL amyloidosis patients who met the criteria of
ASCT could be included. Treatment schedule consisted of two cycles of BD
induction therapy (bortezomib 1.3 mg/m2 and dexamethasone 40 mg/d on
days 1, 4, 8 and 11 followed by 10 days of rest), ASCT treatment (the condi-
tioning regimen consisted of melphalan and bortezomib, the dose of borte-
zomib was 1 mg/m2 on days 6, 3, +1, +4), and four additional 21-day
cycles of bortezomib treatment (with a dose of 1.6 mg/m2 on days 1 and 8
of the cycle) will be conducted as consolidation therapy after ASCT. Hema-
tologic response, tolerability and survival were observed.
